Ciprofloxacin

Generic Name: Ciprofloxacin

Brand Names: Cetraxal, Ciloxan, Cipro, Cipro HC, Ciprodex, Ciprofloxacin, Otiprio, Otixal, Otovel, Proquin

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈FN_₃O_₃

CAS Number: 85721-33-1

Unique Ingredient Identifier: 5E8K9I0O4U

Background: Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.

The first ciprofloxacin containing product was FDA approved on 22 October 1987.

Indication: Ciprofloxacin is only indicated in infections caused by susceptible bacteria.
...

Associated Conditions: Acute Exacerbations of Chronic Bronchitis caused by Moraxella catarrhalis, Acute Otitis Externa, Acute Otitis Externa caused by Pseudomonas Aeruginosa, Acute Otitis Media (AOM), Acute Sinusitis, Acute Uncomplicated Pyelonephritis, Bone and Joint Infections, Chronic Otitis Media, Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Conjunctivitis caused by Haemophilus influenzae, Conjunctivitis caused by Staphylococcus epidermidis, Corneal Ulcers caused by Serratia marcescens, Corneal Ulcers caused by Staphylococcus aureus, Corneal Ulcers caused by Staphylococcus epidermidis, Corneal Ulcers caused by Streptococcus Pneumoniae, Corneal Ulcers caused by Streptococcus Viridans Group, Corneal Ulcers caused by pseudomonas aeruginosa, Escherichia urinary tract infection, External ear infection NOS, Febrile Neutropenia, Infection of the outer ear caused by susceptible bacteria, Infectious diarrhea, Inhalational Anthrax, Lower respiratory tract infection caused by Enterobacter cloacae, Lower respiratory tract infection caused by Escherichia coli, Lower respiratory tract infection caused by Haemophilus influenzae, Lower respiratory tract infection caused by Haemophilus parainfluenzae, Lower respiratory tract infection caused by Klebsiella pneumoniae, Lower respiratory tract infection caused by Proteus mirabilis, Lower respiratory tract infection caused by penicillin-susceptible Streptococcus pneumoniae, Nosocomial Pneumonia, Otitis Media (OM), Otitis Media, Purulent, Plague caused by Yersinia pestis, Skin Infections, Typhoid fever caused by Salmonella typhi, UTI caused by Citrobacter diversus, UTI caused by Citrobacter frendii, UTI caused by Entercococcus faecalis, UTI caused by Enterobacter cloacae, UTI caused by Klebsiella pneumoniae, UTI caused by Morganella morganii, UTI caused by Proteus mirabilis, UTI caused by Providencia rettgeri, UTI caused by Pseudomonas aeruginosa, UTI caused by Serratia marcescens, UTI caused by methicillin-susceptible Staphylococcus epidermidis, Uncomplicated Urinary Tract Infections, Acute otitis externa caused by Staphylococcus aureus, Acute, uncomplicated Cystitis caused by Escherichia coli, Acute, uncomplicated Cystitis caused by Staphylococcus saprophyticus, Chronic Prostatitis caused by Escherichia coli, Chronic Prostatitis caused by Proteus mirabilis, Complicated Pyelonephritis caused by Escherichia coli, Complicated Urinary Tract Infection caused by Escherichia Coli, Uncomplicated Gonorrhea caused by Neisseria gonorrhoeae

Associated Therapies: -

Clinical Trials

Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag

Phase 1

Completed

Conditions: Purpura, Thrombocytopaenic, Idiopathic

Interventions: Drug: Placebo
Drug: Ciprofloxacin
Drug: Eltrombopag

First Posted Date: 2008-06-02

Last Posted Date: 2017-11-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT00688272

Locations: 🇬🇧
GSK Investigational Site, Dundee, United Kingdom

Trial to Evaluate the Efficacy and Safety of Cipro® XR in Treating Female Patients With Lower Urinary Tract Infections

Phase 4

Completed

Conditions: Urinary Tract Infection

Interventions: Drug: Ciprofloxacin

First Posted Date: 2008-05-01

Last Posted Date: 2014-12-19

Lead Sponsor: Bayer

Target Recruit Count: 180

Registration Number: NCT00669994

Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects

Phase 1

Completed

Conditions: Gastroenteritis Escherichia Coli

Interventions: Drug: Ciprofloxacin
Biological: Peru-15-pCTB
Other: Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer

First Posted Date: 2008-04-07

Last Posted Date: 2021-07-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 62

Registration Number: NCT00654108

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States

Ciprofloxacin for the Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease

Phase 2

Completed

Conditions: Crohn's Disease

Interventions: Drug: Placebo
Drug: Ciprofloxacin

First Posted Date: 2008-02-07

Last Posted Date: 2013-05-03

Lead Sponsor: University of North Carolina, Chapel Hill

Target Recruit Count: 33

Registration Number: NCT00609973

Locations: 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States

Efficacy and Safety of Cefditoren Pivoxil Versus Ciprofloxacin in Acute Uncomplicated Cystitis

Phase 3

Completed

Conditions: Urinary Tract Infections

Interventions: Drug: cefditoren pivoxil
Drug: Ciprofloxacin

First Posted Date: 2008-01-21

Last Posted Date: 2010-06-29

Lead Sponsor: Tedec-Meiji Farma, S.A.

Target Recruit Count: 611

Registration Number: NCT00598403

Locations: 🇪🇸
CAP Remei, Vic, Barcelona, Spain
🇪🇸
CAP Florida Nord, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸
CS Basurto, Bilbao, Vizcaya, Spain

and more 27 locations

Impact of Antibiotic Treatment on Prostate-Specific Antigen (PSA) Variability

Phase 4

Terminated

Conditions: Prostate Infections

Interventions: Drug: Placebo
Drug: Ciprofloxacin hydrochloride

First Posted Date: 2008-01-17

Last Posted Date: 2017-01-23

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 31

Registration Number: NCT00596453

Locations: 🇺🇸
Johns Hopkins Hospital Outpatient Center, Baltimore, Maryland, United States

Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)

Phase 3

Completed

Conditions: Breast Cancer
Cyclophosphamide
High Risk
Doxorubicin
Positive Nodes

Interventions: Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: G-CSF
Drug: tamoxifen
Drug: ciprofloxacin

First Posted Date: 2008-01-11

Last Posted Date: 2017-08-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00590785

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia

Phase 3

Conditions: Brain and Central Nervous System Tumors
Lymphoma
Neutropenia
Psychosocial Effects of Cancer and Its Treatment
Small Intestine Cancer
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2007-03-09

Last Posted Date: 2013-08-12

Lead Sponsor: Clatterbridge Centre for Oncology

Target Recruit Count: 400

Registration Number: NCT00445497

Locations: 🇬🇧
Peterborough Hospitals Trust, Peterborough, England, United Kingdom
🇬🇧
Airedale General Hospital, West Yorkshire, England, United Kingdom
🇬🇧
Northampton General Hospital, Northampton, England, United Kingdom

and more 7 locations